enoxaparin + placebo

This entry refers to a combination used in clinical trials where one group receives enoxaparin and the other receives a placebo, rather than a marketed fixed-dose combination product. Enoxaparin is a low molecular weight heparin (LMWH) anticoagulant that inhibits clot formation by potentiating the activity of antithrombin III, leading to inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). Placebo is an inert substance with no pharmacological effect, used as a control in clinical studies. Enoxaparin is primarily indicated for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for reducing ischemic complications in unstable angina or myocardial infarction. The combination "enoxaparin + placebo" does not represent an actual therapeutic regimen but rather denotes arms in randomized controlled trials comparing enoxaparin against an inactive comparator[10][8].

Other names

placebo for enoxaparinsaline placebo (when used as a comparator in trials)